Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-molecule payloads. ADCs demonstrate specific cell killing in clinic, but the basis of their antitumor activity is not fully understood. In this study, we investigated the degree to which payload release predicts ADC activity in vitro and in vivo. ADCs were generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and we found that the intracellular concentration of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios. Intratumoral MMAE concentrations consistently correlated with the extent of tumor growth inhibition in tumor xenograft models. 
Introduction
Antibody-drug conjugates (ADC) are targeted therapies consisting of three components: an antibody targeting a specific tumor antigen, a linker, and a potent payload. Recent advances in these ADC technologies have resulted in two FDA-approved drugs (ADCETRIS and KADCYLA) and more than 30 ADCs in clinical trials (1). The remarkable clinical response to ADCETRIS validates the potential of ADCs as cancer drugs (2, 3) .
Currently, payloads utilized in ADCs primarily include microtubule-disrupting agents [e.g., monomethyl auristatin E (MMAE) and maytansinoid-derived DM1 and DM4] and DNA-crosslinking agents [e.g., calichaemicin and pyrrolobenzodiazepines (PBD) dimers]. Although ADCs have demonstrated clinical and preclinical activity, it has been unclear what factors determine such potency in addition to antigen expression on targeted tumor cells. For example, drug:antibody ratio (DAR), ADC-binding affinity, potency of the payload, receptor expression level, internalization rate, trafficking, multiple drug resistance (MDR) status, and other factors have all been implicated to influence the outcome of ADC treatment in vitro (4-7). Thus, it is difficult to compare activity of different ADCs across cell lines, due to multiple variable parameters. Indeed, two studies found no correlation between cell surface CD22 expression and the activity of ADCs targeting CD22 (using either MMAE or DM1; refs. 8, 9) , demonstrating the complexity of the multiple mechanisms contributing to ADC activity.
In addition to the direct killing of antigen-positive tumor cells, ADCs also have the capacity to kill adjacent antigennegative tumor cells: the so-called "bystander killing" effect (10) . In vitro, this capacity has been observed in colony assays and coculture systems. For example, huC242-DM1 ADCs were found to mediate bystander killing using a colony coculture assay in vitro and an admixed tumor model in vivo (11) . Similarly, intracellular released MMAE was reported to mediate bystander killing in a coculture system (12) . Recently, Breij and colleagues suggested such bystander activity is relevant in patient-derived xenograft models (13) . Although these studies provide examples of bystander killing, the underlying factors controlling this property remain to be defined. Here, we studied two key parameters of ADCs: (i) the relationship between the concentration of the released payload and ADC potency in vitro and in vivo and (ii) the relationship between the membrane permeability of the released payload and the extent of ADC bystander killing. By targeting different receptors capable of internalization and lysosomal trafficking on L-82 cancer cells using ADCs with various drug:antibody ratios (DAR), we determined how the concentration of the released MMAE correlated with in vitro cytotoxic response and in vivo antitumor activity. We found that intratumoral MMAE concentration correlated with antigen-specific antitumor activity in vivo. The roles of linker chemistry and the biophysical nature of the payload in this bystander killing were also studied.
Materials and Methods
Cell culture Karpas 299 and L-82 cells were obtained from Dr. Abraham Karpas of the University of Cambridge and from the German Collection of Microorganisms and cultures (DSMZ). The Karpas-35R cell line was derived from Karpas 299 by continuous exposure to cAC10-vcMMAE, and they were confirmed as derivative of Karpas 299 using SNP fingerprint analysis by the ATCC. Cells were grown in RPMI1640 media (Invitrogen) containing 10% FBS and 100 U/mL Penicillin and Streptomycin in a 37 C humidified incubator with 5% CO 2 . For cytotoxicity assays, cells were plated at an average density of 7,000 to 10,000 per well in 96-well tissue culture plates and incubated with ADCs for 72 hours or 96 hours. Each assay was performed in triplicate. Cell viability was determined using CellTiter-Glo (Promega), and IC 50 values were calculated using GraphPad Prism.
In vivo antitumor activity study
All animal studies were conducted following Institutional Animal Care and Use Committee protocols. For xenograft studies, 5 million Karpas 299 or Karpas-35R cells were implanted subcutaneously into SCID mice (Harlan). The admixed tumor model was implanted with a mixture containing 2.5 million Karpas 299 and 2.5 million Karpas-35R cells. To titrate CD30 þ cells in admixed tumor model, a total of 5 million cells were implanted in each mouse, whereas the number of Karpas 299 and Karpas-35R cells was adjusted to achieve the ratios of 10%, 25%, and 50% CD30 þ Karpas 299 cells. One million L-82 cells were implanted subcutaneously to NOD SCID IL2Rgamma null (NSG) mice for xenograft studies (Jackson Laboratory). Treatment was initiated when the average tumor size reached at least 100 mm 3 for tumor efficacy studies. To measure released payload in tumors, treatment was initiated at 250 to 400 mm 3 . Tumors were measured twice a week, and the volume was calculated with the formula volume ¼ 1/2 Â length Â width Â width.
Flow cytometry
Receptor expression on Karpas 299, Karpas-35R, and L-82 cells was quantified using QIFIKit following the manufacturer's instructions (Dako). The monoclonal antibodies used to measure CD30, CD70, and CD71 surface expression were BerH2 (BD Biosciences), h1F6 (14) , and chimeric OKT9. Chimeric OKT9 was developed from mouse hybridoma cell line OKT9 (ATCC). Flow cytometry of CD30 on Karpas-35R cells and admixed tumors was performed using mouse monoclonal antibody BerH2 conjugated with R-phycoerythrin or isotype control (BD Biosciences), and CD45 conjugated with allophycocyanin (BD Biosciences). Stained cells were analyzed on FACS Calibur (BD).
Immunohistochemistry
Tumors were fixed in 10% neutral buffered formalin, embedded in paraffin, and sections were cut at 4-mm thickness. Staining including de-paraffinization and heat-induced target retrieval in the presence of EDTA was done on a Bond autostainer (Leica Biosystems). Bond autostainer reagents were used for antibody detection, nuclear counterstain, and buffer rinses. The following primary antibodies were applied: rabbit anti-CD71 polyclonal antibody (Proteintech Group) and mouse monoclonal anti-CD30 Clone BerH2 (Dako). For detection, horseradish peroxidase-3,3
0 -diaminobenzidine (HRP-DAB) was used for CD30 IHC (Bond Polymer Refine DAB Kit), and alkaline phosphatase-fast red was used for CD71 (Bond Polymer Refine Red Kit). Hematoxylin was used to counter stain nuclei. Images were acquired on an Olympus BX41 microscope equipped with a Nikon DS-Fi1 camera.
Antibody-drug conjugation
The syntheses of MMAE, MMAF, and PBD dimers have been described previously (6, 15, 16) . ADCs were prepared using valine-citrulline (vc)-PAB linkers with an average drug loading of 4 (15), unless specified otherwise. The glucuronide linker and PBD linker conjugation has been described elsewhere (16, 17) .
Intracellular and intratumoral drug measurement by LC-MS
Cell pellets were collected 24 hours after ADC treatment. Cell count, diameter, and circularity were determined on Vi-Cell Counter (Beckman Coulter). MMAE extraction and quantification method was identical to the protocol described in Okeley and colleagues (12) . Briefly, tumors or cell pellets were homogenized with methanol and acetonitrile containing internal standard (d 8 -MMAE for MMAE detection and 13 C-MMAF for MMAF detection). The homogenates were centrifuged at 10,000 rpm to precipitate protein and protein-bound payloads. The supernatant was then subjected to solid phase extraction, and signals of MMAE and MMAF were detected by LC-MS.
Measurement of ADCs in plasma
Micro-titer plates were coated overnight with a murine IgG1 mAb with specificity to human light chain kappa (Jackson ImmunoResearch), or an anti-idiotype mAb that binds to cAC10. Samples were diluted into the dynamic range of the assay with na€ ve mouse plasma. After a 1:40 dilution into assay diluent, standards, controls, and samples were incubated on the coated and blocked plates. Bound ADCs were detected with HRP-conjugated goat polyclonal antibody reagent with specificity to the Fc region of human IgG (Jackson ImmunoResearch). After incubation and subsequent washing, 3,3 0 ,5,5 0 tetramethylbenzidine was applied to the wells and the signal measured by absorbance at OD450 nm-OD630 nm.
Results
The intracellular concentration of released MMAE drives ADC cytotoxicity and potency in vitro It has been shown that ADCs bind to tumor cells in vitro and release payload inside cancer cells upon trafficking to the appropriate subcellular organelles, e.g., lysosomes (12, 18, 19) . Since the released payload is the active component of the ADC, we sought to evaluate whether the amount of released payload is correlated with ADC activity by targeting the anaplastic large cell lymphoma (ALCL) cell line L-82, which expresses CD30, CD70, and CD71 (transferrin receptor) simultaneously ( Fig. 1A ; ref. 20 ). An in vitro cytotoxicity assay of ADCs targeting CD30 (cAC10-vcMMAE, with a DAR of 2, 4, or 8), CD70 (h1F6-vcMMAE with a DAR of 4), or CD71 (cOKT9-vcMMAE with a DAR of 4) was used to determine the in vitro potency of these ADCs. Their IC 50 values varied from 2 ng/mL to 55 ng/mL, which may reflect the variance of antigen expression level, internalization rate, and DAR (Fig. 1B) , consistent with our previous report (21) .
We then assessed how much MMAE was released inside L-82 cells after the treatment with these five ADCs at their respective IC 50 concentrations. Interestingly, the intracellular MMAE concentrations from these ADCs were similar, ranging between 98 nmol/L to 150 nmol/L, a variance of only approximately 1.5-fold in contrast with the >20-fold difference in their IC 50 values (Fig.  1C) . These results indicate that the concentration of released MMAE determines the extent of cell killing in vitro, independent of antigen expression level or DAR.
The intratumoral concentration of MMAE correlates with ADC antitumor activity in vivo
We then evaluated whether released MMAE correlates with ADC potency in vivo. To minimize the effects of drug loading on ADC pharmacokinetics in vivo (21), we only tested ADCs with four MMAE molecules per antibody, conjugated to cAC10, cOKT9, or h1F6. After a single dose of cAC10-vcMMAE treatment, L-82 tumors either had no response (0.5 mg/kg), growth delay (1 mg/kg), or complete remission (3 mg/kg). Similarly, cOKT9-vcMMAE and h1F6-vcMMAE demonstrated dose-dependent antitumor response in the L-82 xenografts ( Fig. 2A) . Interestingly, despite their different in vitro potencies (Fig. 1A and B) , L-82 xenografts responded similarly to cAC10-vcMMAE, h1F6-vcMMAE, and cOKT9-vcMMAE ( Fig. 2A) . We also used LC-MS to measure the concentration of MMAE in a parallel cohort of L-82 tumors with an identical treatment regimen. Although tumor volume was not different among treatment groups 3 days after dose, the intratumoral MMAE measurement revealed two patterns (Fig. 2B) . First, intratumoral MMAE concentration increased proportionally to the ADC dose, which corresponded to stronger antitumor activity. Second, the intratumoral MMAE concentration obtained from treatment with both cOKT9-vcMMAE and cAC10-vcMMAE was similar at each dose, consistent with the observation that tumor responded similarly to these two ADCs ( Fig. 2A) . These results indicate that the intratumoral concentration of MMAE determines the antitumor activity of ADCs in vivo, independent of antigen expression level, as was the case for in vitro treatments.
Intratumoral MMAE correlates with antigen-specific antitumor activity in Karpas 299 xenograft
To directly determine how released MMAE correlates with ADC potency in vivo, we treated CD30 þ , ALCL cell line Karpas 299 tumor-bearing SCID mice with cAC10-vcMMAE, or nonbinding IgG-vcMMAE, followed by measurement of plasma ADC, plasma MMAE, as well as intratumoral released MMAE concentration. A single dose of 2 mg/kg cAC10-vcMMAE treatment resulted in tumor regression within 10 days, whereas IgGvcMMAE had no impact on tumor growth (Fig. 3A) . This observation is consistent with our previous report of cAC10-vcMMAE-specific antitumor activity in Karpas 299 cell model (22) . Concordantly, intratumoral MMAE concentration measurement revealed a clear separation between cAC10-vcMMAE and IgG-vcMMAE-treated animals (Fig. 3B) activity. The profiles of cAC10-vcMMAE and IgG-vcMMAE were similar in plasma, with an average half-life of 6.7 days for cAC10-vcMMAE ( Supplementary Fig. S1A ). The plasma concentration of MMAE in both treated groups was around 2 nmol/L at 4 hours after dose, but cleared quickly in circulation (Supplementary Fig.  S1B ). These data collectively show: (i) targeted ADCs deliver a high concentration of MMAE to tumor, (ii) the amount of intratumoral released MMAE correlates with ADC antitumor activity, and (iii) the amounts of released MMAE determined the extent of cytotoxicity in vitro and in vivo.
Development of admixed tumor model with heterogeneous CD30 expression
We have recently developed Karpas-35R cells (resistant to cAC10-vcMMAE treatment) from the Karpas 299 cell line through continuous exposure to . This derivative cell line has lost surface CD30 expression but has retained CD71 expression as confirmed by flow cytometric analysis (Supplementary Fig. S2A ). The absence of CD30 prevented cell killing by cAC10-vcMMAE or cAC10-vcMMAF (IC 50 > 5 mg/mL) in vitro. However, Karpas-35R cells remain sensitive to CD71 binding ADCs such as cOKT9-vcMMAE and cOKT9-vcMMAF (IC 50 1$4 ng/mL; Fig. 4A ). In vivo, Karpas-35R tumors and Karpas 299 tumors grew at similar rates when implanted subcutaneously in SCID mice. Karpas-35R cells remained CD30 negative and hence were insensitive to cAC10-vcMMAE treatment in vivo, while they were eradicated by cOKT9-vcMMAE ( Supplementary Fig. S2B ).
These results prompted us to mix Karpas 299 and Karpas-35R cells to develop a tumor model consisting of both CD30 þ and CD30 À cells. A 1:1 ratio mixture of Karpas 299 and Karpas-35R cells grew together at a similar rate to those tumors from individual cell lines (Fig. 4B) . IHC staining revealed a heterogeneous CD30 expression pattern in the admixed tumors, unlike the homogeneous CD30 expression in Karpas 299 tumors or absence of CD30 in Karpas-35R tumors (Fig. 4C) . Importantly, the CD30 þ and CD30 À cells formed an interspersed pattern, resembling the distribution seen in analyses of human tumors (24) . IHC analysis also confirmed comparable CD71 expression in Karpas 299, Karpas-35R, and the admixed tumors (Fig. 4C ). FACS analysis also demonstrated coexistence of CD30 þ and CD30 À cells in admixed tumors ( Supplementary Fig. S3A )
MMAE, but not MMAF, mediates bystander killing in vivo
We then studied the in vivo bystander killing potential of two potent auristatin payloads, MMAE and MMAF, in this admixed tumor model. MMAE and MMAF are structurally similar, and cAC10-vcMMAE and cAC10-vcMMAF were both potently cytotoxic to Karpas 299 cells (Fig. 4A) . However, MMAF is a more hydrophilic molecule and less membrane permeable than MMAE (6) . In general, MMAF has a higher IC 50 than MMAE in cell lines (Fig. 5A) , consistent with its lower membrane permeability.
After cAC10-vcMMAE (3 mg/kg, once i.p.) treatment, the admixed tumors underwent complete remission within 1 week after dose. Three of the five tumors remained in remission for 4 weeks. In contrast, cAC10-vcMMAF caused only a moderate growth delay but no complete remissions (Fig. 5B) . Nontargeting controls IgG-vcMMAE or IgG-vcMMAF did not affect tumor growth of the admixed tumors, whereas positive controls (cOKT9-vcMMAE and cOKT9-vcMMAF) targeting CD71 led to complete remissions (Fig. 5B ). This experiment indicated that complete tumor remission could result from bystander killing of MMAE.
IHC analysis revealed that nonbinding control-treated tumors consist of both CD30 þ and CD30 À cells, presumably because they do not kill either CD30 þ or CD30 À Karpas 299 cells. Only CD30 À cells were found in cAC10-vcMMAF-treated tumors, illustrating that cAC10-vcMMAF eliminated most CD30 þ cells (Fig. 5C) .
Interestingly, the two tumors that relapsed from cAC10-vcMMAE treatment were also found to be CD30 À by the end of study, indicating a small fraction of CD30 À cells might have escaped from bystander killing in these two remaining tumors (Fig. 5C) . We also performed LC-MS analysis of admixed tumors treated Table S1 ). Continuous tumor growth in the cAC10-vcMMAF treatment group was therefore likely because released MMAF could not diffuse into neighboring CD30 À cells. Collectively, these results demonstrate intratumoral released MMAE, but not MMAF, can mediate potent bystander killing in vivo.
Conjugation of MMAE using a glucuronide linker maintains bystander killing in vivo
Encouraged by the result that the admixed tumor model can differentiate a payload's bystander killing property, we then evaluated the role of the linkers in bystander killing by comparing MMAE conjugated to cAC10 using either peptide (cAC10-vcMMAE) or b-glucuronide (cAC10-glucMMAE; Fig. 6A; ref. 17) linkers. Complete remission of the admixed tumors was observed after a single dose of cAC10-vcMMAE or cAC10-glucMMAE (Fig. 6B) . As a control, intratumoral MMAE measurement confirmed 320 nmol/L and 490 nmol/L MMAE was released from cAC10-vcMMAE and cAC10-glucMMAE, respectively (Supplementary Table S2 ). These results suggest that both of the cleavable linkers are releasing MMAE and can mediate bystander killing in vivo.
Potent bystander killing activity of PBD conjugates in vivo
The DNA cross-linking PBD dimers have empowered ADCs to overcome the multiple drug resistance phenotype observed in acute myeloid leukemia (5, 16) . Based on their membrane permeable nature in vitro (5), we hypothesized that PBDs may also have bystander killing potential. We engineered the cAC10 antibody to enable site-specific conjugation of two PBD molecules per antibody by replacing the heavy chain serine residue at position 239 with a cysteine (cAC10ec-PBD; Fig. 6C; ref. 5) . Remarkably, cAC10ec-PBD treatment (0.1 mg/kg, once i.p.) resulted in complete remission of the admixed tumors in 5 of 5 (100%) animals (Fig. 6D) . In contrast, nonbinding IgGec-PBD did not delay tumor growth. These data demonstrate that PBD-based ADCs can initiate potent local bystander killing in vivo.
Antigen expression for PBD and MMAE-mediated bystander killing
The high potency of a PBD payload suggested that it may require fewer antigen-positive cells to enable bystander killing activity than MMAE. To test this, admixed tumors were generated with a titration comprising Karpas 299 cells from 10% to 25% and 50%. CD30 IHC of the resulting admixed tumors (200 mm 3 ) confirmed a corresponding increase in CD30 þ cell percentage (Fig. 7A) . Flow cytometric analysis of dissociated tumors also confirmed increasing CD30 þ cell percentage in the admixed tumors (34%, 61% and 69% CD30 þ cells, respectively; Fig. 7B and Supplementary Table S3 ). Interestingly, tumors consisting of 69% and 61% CD30 þ Karpas 299 cells underwent remission after cAC10-vcMMAE or cAC10ec-PBD treatment. However, tumors consisting of 34% Karpas 299 cells regressed subsequent to cAC10ec-PBD treatment, whereas cAC10-vcMMAE only caused a growth delay (Fig. 7C-E) . These results argue that PBD ADCs may require fewer CD30 þ cells to mediate bystander killing in vivo, presumably due to its superior potency.
Discussion
With recent approval of ADCETRIS and KADCYLA, ADCs have become major players in oncology drug development pipelines, as a result of the advancement in areas such as antigen selection, linker chemistry, and payload optimization (25) . However, the challenge remains to select the appropriate cancer target, payload, and linker to identify lead ADC candidates, mainly due to the incomplete understanding of what factors drive of ADC activity in the tumor microenvironment.
Released drug and ADC activity correlation
Here, we studied the role of released payload within the L-82 cell line by alternating target antigen and drug loading. This allowed us to compare ADC activity of multiple ADCs without other variables such as drug sensitivity and efflux status, which may have confounded studies comparing multiple cell lines (8, 9) . While our data suggest that antigen expression and DAR can affect ADC potency, these factors are not restrictive. In contrast, intracellular released payload appears to determine ADC potency in vitro. Importantly, the amount of released MMAE also determines the antitumor activity of ADC in vivo, independent of antigen expression, suggesting the ADC design shall aim to improve intratumoral payload delivery. For example, a recent conjugation method allowing higher drug antibody ratio may help deliver more drug to tumors (26) .
It has been challenging to predict pharmacodynamics responses using traditional pharmacokinetic parameters such as total antibody and small-molecule concentrations (27, 28) . Our parallel measurement of plasma ADC, plasma MMAE, and intratumoral released MMAE suggests that intratumoral released MMAE concentration correlates best with antitumor activity in xenograft models. Although this observation is encouraging, correlation between the intratumoral released payload concentrations and the clinical response to ADCs in patients remains to be tested.
Modeling bystander killing in vivo
Part of the remarkable clinical response to cAC10-vcMMAE has been attributed to the bystander killing effect of ADCs (2, 29) . This capacity may distinguish ADCs from each other in solid cancers, where target heterogeneity is common (11, 30) . There is an absolute requirement for target expression in order to obtain antitumor activity. Therefore, several studies have tried to understand bystander killing in vitro and in vivo (11-13, 30, 31) . While in vitro studies are informative, they often lack the close cell-to-cell contact, which may limit the study of the phenotype. Admixed tumor models mimicking heterogeneous expression have been reported (11, 13) . However, we have discovered that mixing two distinct cell types, one expressing the target of interest and the other does not, often led to outgrowth of a single-cell population or spatial segregation of antigen-positive and -negative cells as reported in other studies [data not shown (11) critical to develop admixed tumor models. Recently, a related approach employing HT-26 cells engineered to overexpress mesothelin was used to study the bystander killing of BAY 94-9343, an anti-mesothelin maytansine ADC (31) . Based on these observations, we propose these criteria for robust bystander killing models: (i) the targeted cell line expresses the antigen of interest in their cell surface; (ii) the bystander cell line lacks the targeted antigen and is insensitive to the testing ADC; (iii) testing doses are within the specific range where nonbinding ADCs are not active on either cell line; and (iv) the target-positive and targetnegative cells are interspersed throughout the tumor.
The role of linker, payload, and target cells in bystander killing Intratumoral MMAE released from cAC10-vcMMAE kills both CD30 þ cells and CD30 À cells in vivo, whereas another auristatin payload, MMAF, lacked such capacity. These data argue that membrane permeability and the ability of the released payload to diffuse through the tumor are required for bystander killing. In line with this argument, the membrane permeable PBD dimer was also found to mediate bystander killing. Therefore, it is important to evaluate engineered payload for their membrane permeability and bystander killing. The role of linkers in bystander killing has been unclear, partly due to introduction of "non-cleavable" linkers. For example, it has been reported that a noncleavable linker may abolish the bystander killing capacity of DM1 (11) . However, it is important to note that this noncleavable linker releases a modified payload (e.g., T-DM1 releases lysine-MCC-DM1 instead of DM1; ref. 32); the membrane permeability and potency of lysine-MCC-DM1 may be drastically different from that of DM1. In the present study, we found two different linkers (b-glucuronide and vc-PAB), both release MMAE and mediate bystander killing similarly in vivo. These results demonstrate that the bystander killing property is mainly determined by the biophysical properties of the released payload, as opposed to the specific details of the linker and the mechanism of drug release.
The role of antigen-positive cancer cells in bystander killing is also evaluated in this study. As expected, a higher percentage of target-positive cells in admixed tumors leads to more pronounced tumor regression. Interestingly, the extent of bystander killing can be related to payload potency. Our results suggest that PBD-based ADCs can mediate bystander killing in admixed tumors with as little as 34% antigen-positive cells while MMAE-based ADCs required higher percentages. Hence, the abundance of antigenpositive cell required for bystander killing may vary according the payload potency.
These findings collectively argue that the locally released payload from the ADC determines the activity of killing of tumor cells and bystander cells. This is particularly important for selecting appropriate payload for novel tumor antigens. Heterogeneity of antigen expression often presents obstacle for ADC development in solid tumors; therefore, a membrane permeable payload may provide maximal killing of tumor cells (11) . In contrast, when antigen expression is homogeneous on cancer cells (e.g., CD19 and CD79b 
